@article {LePAGE756, author = {G. A. LePAGE and ABDUL KHALIQ and J. A. GOTTLIEB}, title = {STUDIES OF 9-β-D-ARABINOFURANOSYLADENINE IN MAN}, volume = {1}, number = {6}, pages = {756--759}, year = {1973}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {9-β-D-Arabinofuranosyladenine was given to two patients by relatively rapid ({\textonehalf}, 2 hr) intravenous infusion, to two patients as a continuous intravenous drip over 24 hr, and to two patients as an intramuscular suspension. Blood plasma levels and urinary excretion of ara-A1 and the chief metabolic product. 9-β-D-arabinofuranosylhypoxanthine, were measured at intervals up to 24 hr. Rapid intravenous infusions resulted in 88 and 97\% recoveries in urine by 24 hr, as ara-H and ara-A. Urinary excretion after administration as a continuous intravenous drip was 33 and 41\%, respectively, in the first 24 hr. The two patients receiving intramuscular injection excreted only 1.7 and 7.1\% of the dose, respectively, in 24 hr. The latter finding would indicate poor absorption of an intramuscular dose. Copyright {\textcopyright} 1973 by The American Society for Pharmacology and Experimental Therapeutics}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/1/6/756}, eprint = {https://dmd.aspetjournals.org/content/1/6/756.full.pdf}, journal = {Drug Metabolism and Disposition} }